Neonatal conjunctivitis is a form of eye inflammation affecting newborn infants. At our company, we are committed to advancing the development of innovative vaccines and therapies to combat this infectious disease.
Introduction to Neonatal Conjunctivitis
Neonatal conjunctivitis, also known as ophthalmia neonatorum, is an inflammation of the conjunctiva in newborns, typically occurring within the first month of life. It can be caused by various infectious agents, including bacteria such as Neisseria gonorrhoeae and Chlamydia trachomatis, as well as viruses like herpes simplex virus (HSV). Non-infectious causes can also be due to chemical irritants or blocked tear ducts. If left untreated, this condition can lead to severe complications such as blindness, emphasizing the urgency for effective prevention and therapeutic strategies.
Fig.1 Reference data on the distribution of resistance to different antibiotics. (Kara M., et al., 2018)
Vaccine Development for Neonatal Conjunctivitis
Developing an effective vaccine against the primary infectious agents responsible for neonatal conjunctivitis has been an area of active research and clinical investigation. By stimulating the immune system to mount a protective response, a vaccine could potentially prevent the devastating consequences of this condition.
One of the key challenges in neonatal conjunctivitis vaccine development is the need to elicit a robust, targeted immune response in newborns, whose immune systems are still maturing. Researchers have explored various approaches, including leveraging adjuvants, modifying antigen formulations, and optimizing delivery routes to enhance the immunogenicity of candidate vaccines.
Therapeutics Development for Neonatal Conjunctivitis
The development of drugs and therapies for neonatal conjunctivitis is a multidisciplinary effort, involving microbiology, immunology, pediatrics, and ophthalmology. The goal is to create safe and effective therapeutics that can prevent or mitigate the disease in newborns.
Antimicrobial Agents
The development of antimicrobial agents focuses on identifying and formulating drugs that target specific pathogens causing neonatal conjunctivitis. For bacterial infections, antibiotics such as ceftriaxone and erythromycin are commonly used. For viral infections, antiviral drugs like acyclovir are considered.
Systemic and Topical Therapies
Deciding between systemic and topical administration of these drugs is critical. Systemic administration ensures adequate drug levels throughout the body, while topical administration can reduce systemic side effects and target the infection directly at the site.
Our Services
At our company, we pride ourselves on our comprehensive suite of services dedicated to advancing the development of neonatal conjunctivitis vaccines and therapies. Our multidisciplinary team of experts, encompassing immunologists, microbiologists, pharmacologists, and preclinical researchers, collaborates seamlessly to drive innovation and ensure the successful progression of your projects.
Preclinical Research
- Drug Safety Evaluation
- In Vivo Pharmacokinetics Study
- In Vitro Pharmacokinetics Study
- Activity Testing
- Drug Resistance Evaluation
Disease Models
- N. gonorrheae Induced Conjunctivitis
- Chlamydia Induced Conjunctivitis
- Herpes simplex virus (HSV 2) Induced Conjunctivitis
- Staphylococcus aureus Induced Conjunctivitis
- Streptococcus pyogenes Induced Conjunctivitis
Our data-driven approach and adherence to industry-leading standards ensure the delivery of high-quality, reliable results that can bolster your drug and vaccine development programs. If our services have piqued your interest, we warmly welcome you to reach out to us for further information and to obtain a detailed quotation for the services you require.
References
- Kara Mustafa, et al. "The newborn conjunctival flora at the post delivery 24 hours." Journal of Current Ophthalmology 30.4 (2018): 348-352.
- Makker Kartikeya, George N. Nassar, and Evan J. Kaufman. "Neonatal conjunctivitis." (2017).
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
